Asymmetric dimethylarginine reduces nitric oxide donor-mediated dilation of arterioles by activating the vascular renin-angiotensin system and reactive oxygen species

Journal of Vascular Research

Volumn 49, Issue 4, 2012, Pages 363-372

  Veresh, Zoltan ^a,b   Debreczeni, Bela ^c   Hamar, Janos ^c   Kaminski, Pawel M ^a   Wolin, Michael S ^a   Koller, Akos ^a,c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Arteriolar dilation; Asymmetric dimethylarginine; Nitric oxide; Oxidative stress; Reactive oxygen species; Vascular renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE REDUCTASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PYROGALLOL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ARTERIOLE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MECHANISM; ENZYME INHIBITION; GRACILIS MUSCLE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION;

ACETOPHENONES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARGININE; ARTERIOLES; CATALASE; MALE; MUSCLE, SKELETAL; NADPH OXIDASE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; OXIDATIVE STRESS; PYROGALLOL; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SUPEROXIDE DISMUTASE; VASODILATION; XANTHINE OXIDASE;

EID: 84861637356     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000337485     Document Type: Article

References (55)

1. Schmidt HH, Nau H, Wittfoht W, Gerlach J, Prescher KE, Klein MM, Niroomand F, Bohme E: Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 1988; 154: 213-216.
2. Sun D, Messina EJ, Koller A, Wolin MS, Kaley G: Endothelium-dependent dilation to Larginine in isolated rat skeletal muscle arterioles. Am J Physiol 1992; 262:H1211-H1216.
3. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-752. (Pubitemid 20357206)
4. Koller A, Sun D, Messina EJ, Kaley G: L-arginine analogues blunt prostaglandin-related dilation of arterioles. Am J Physiol 1993; 264:H1194-H1199. (Pubitemid 23115293)
5. Boucher JL, Moali C, Tenu JP: Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization. Cell Mol Life Sci 1999; 55: 1015-1028. (Pubitemid 29361068)
6. Kenny D, Coughlan MG, Kampine JP, Montgomery RR, Bosnjak ZJ, Warltier DC: Cultured endothelial cells restore vasodilator responses to coronary arteries with impaired endothelial function and alter the response to a nitric oxide donor. Pharmacology 1994; 49: 249-256. (Pubitemid 24289800)
7. Qiu HY, Henrion D, Levy BI: Alterations in flow-dependent vasomotor tone in spontaneously hypertensive rats. Hypertension 1994; 24: 474-479. (Pubitemid 24296470)
8. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
9. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R: Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128. (Pubitemid 34094905)
10. Hedner T, Himmelmann A, Hansson L: Homocysteine and ADMA-emerging risk factors for cardiovascular disease? Blood Press 2002; 11: 197-200.
11. Zeller M, Korandji C, Guilland JC, Sicard P, Vergely C, Lorgis L, Beer JC, Duvillard L, Lagrost AC, Moreau D, Gambert P, Cottin Y, Rochette L: Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol 2008; 28: 954-960. (Pubitemid 351544113)
12. Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, Minar E, Muller M, Wolzt M, Schillinger M: Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006; 26: 2536-2540. (Pubitemid 44607477)
13. Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, Bengtsson C, Bjorkelund C, Thelle D: Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008; 28: 961-967. (Pubitemid 351544114)
14. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE: Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001; 37: 489-492. (Pubitemid 32240431)
15. Fleck C, Schweitzer F, Karge E, Busch M, Stein G: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 2003; 336: 1-12. (Pubitemid 37336493)
16. Turan F, Ilhan N, Kaman D, Ates K, Kafkasli A: Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and plasma concentrations of asymmetric dimethylarginine in Turkish pre-eclamptic women without fetal growth retardation. J Obstet Gynaecol Res 2010; 36: 495-501.
17. Al-Zobaidy MJ, Craig J, Martin W: Differential sensitivity of basal and acetylcholine-induced activity of nitric oxide to blockade by asymmetric dimethylarginine in the rat aorta. Br J Pharmacol 2010; 160: 1476-1483.
18. Veresh Z, Racz A, Lotz G, Koller A: ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension 2008; 52: 960-966.
19. MacAllister RJ, Fickling SA, Whitley GS, Vallance P: Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112: 43-48. (Pubitemid 24151701)
20. Chen MF, Li YJ, Yang TL, Lou B, Xie XM: Losartan inhibits monocytic adhesion induced by ADMA via downregulation of chemokine receptors in monocytes. Eur J Clin Pharmacol 2009; 65: 457-464.
21. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B, Frolich JC, Boger RH: ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57: 244-252. (Pubitemid 36009457)
22. Bode-Boger SM, Scalera F, Martens-Lobenhoffer J: Asymmetric dimethylarginine (ADMA) accelerates cell senescence. Vasc Med 2005; 10(suppl 1):S65-S71. (Pubitemid 43140639)
23. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N: Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682-1688. (Pubitemid 39180895)
24. Chen MF, Xie XM, Yang TL, Wang YJ, Zhang XH, Luo BL, Li YJ: Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J Vasc Res 2007; 44: 391-402.
25. Yang ZC, Wang KS, Wu Y, Zou XQ, Xiang YY, Chen XP, Li YJ: Asymmetric dimethylarginine impairs glucose utilization via ROS/TLR4 pathway in adipocytes: an effect prevented by vitamin E. Cell Physiol Biochem 2009; 24: 115-124.
26. Toth J, Racz A, Kaminski PM, Wolin MS, Bagi Z, Koller A: Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-mediated increase in arteriolar tone. Hypertension 2007; 49: 563-568.
27. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF: Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000; 101: 2206-2212. (Pubitemid 30253051)
28. Mohazzab KM, Kaminski PM, Wolin MS: NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994; 266:H2568-H2572. (Pubitemid 24215893)
29. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148. (Pubitemid 24176909)
30. Koller A, Sun D, Huang A, Kaley G: Corelease of nitric oxide and prostaglandins mediates flow-dependent dilation of rat gracilis muscle arterioles. Am J Physiol 1994; 267:H326-H332.
31. Bagi Z, Koller A: Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin. J Vasc Res 2003; 40: 47-57. (Pubitemid 36351195)
32. Ignarro LJ, Byrns RE, Buga GM, Wood KS, Chaudhuri G: Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation. J Pharmacol Exp Ther 1988; 244: 181-189. (Pubitemid 18042379)
33. Huang A, Sun D, Kaley G, Koller A: Superoxide released to high intra-arteriolar pressure reduces nitric oxide-mediated shear stress-and agonist-induced dilations. Circ Res 1998; 83: 960-965. (Pubitemid 28503086)
34. Beswick RA, Dorrance AM, Leite R, Webb RC: NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38: 1107-1111. (Pubitemid 34252814)
35. Williams HC, Griendling KK: NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol 2007; 50: 9-16. (Pubitemid 47220441)
36. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T: Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90:E58-E65.
37. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001; 88:E14-E22.
38. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847. (Pubitemid 28509278)
39. Billecke SS, Kitzmiller LA, Northrup JJ, Whitesall SE, Kimoto M, Hinz AV, D'Alecy LG: Contribution of whole blood to the control of plasma asymmetrical dimethylarginine. Am J Physiol Heart Circ Physiol 2006; 291:H1788-H1796. (Pubitemid 44497685)
40. Bogle RG, MacAllister RJ, Whitley GS, Vallance P: Induction of NG-monomethyl-Larginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 1995; 269:C750-C756.
41. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, Aigner C, Fink L, Muyal JP, Weissmann N, Grimminger F, Seeger W, Schermuly RT: Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005; 19: 1175-1177. (Pubitemid 40946456)
42. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-177. (Pubitemid 38114135)
43. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr: Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-9225. (Pubitemid 28506212)
44. Chen YH, Xu X, Sheng MJ, Zheng Z, Gu Q: Effects of asymmetric dimethylarginine on bovine retinal capillary endothelial cell proliferation, reactive oxygen species production, permeability, intercellular adhesion molecule-1, and occludin expression. Mol Vis 2011; 17: 332-340.
45. Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G, Waclawiw MA, Panza JA, Cannon RO 3rd: Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101: 2160-2164. (Pubitemid 30253044)
46. Wells SM, Holian A: Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol 2007; 36: 520-528. (Pubitemid 46676710)
47. Hasegawa K, Wakino S, Tatematsu S, Yoshioka K, Homma K, Sugano N, Kimoto M, Hayashi K, Itoh H: Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res 2007; 101:e2-e10. (Pubitemid 47196589)
48. Desai A, Zhao Y, Warren JS: Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice. Nephrol Dial Transplant 2008; 23: 1513-1520. (Pubitemid 351767760)
49. Schroder H: No nitric oxide for HO-1 from sodium nitroprusside. Mol Pharmacol 2006; 69: 1507-1509.
50. Ciarcia R, Damiano S, Panico C, Scanni R, Fiorito F, Florio S, Welch JW: Apocynin activity in spontaneously hypertensive rats (SHR): preliminary studies in vivo. Vet Res Commun 2010; 34(suppl 1):S83-S86.
51. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
52. Jiang JL, Zhu HQ, Chen Z, Xu HY, Li YJ: Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine level. Int J Cardiol 2005; 101: 153-155. (Pubitemid 40614754)
53. Zhang Q, Chen N, Qiu W, Xu X, Wang D, Tsao PS, Jin H: Asymmetric dimethylarginine impairs fibrinolytic activity in human umbilical vein endothelial cells via p38 MAPK and NF-B pathways. Thromb Res 2011; 128: 42-46.
54. Saijonmaa O, Nyman T, Fyhrquist F: Downregulation of angiotensin- converting enzyme by tumor necrosis factor and interleukin-1 in cultured human endothelial cells. J Vasc Res 2001; 38: 370-378. (Pubitemid 32678952)
55. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK: Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-413. (Pubitemid 35034208)